Patient characteristics at randomization
| Characteristics . | Control . | Intervention . |
|---|---|---|
| n | 16 | 15 |
| Age (years) | 44 (32.3–46.8) | 41.8 (24.4–52.7) |
| Sex (% women) | 11 (68.8) | 10 (66.7) |
| Diabetes duration (years) | 17.2 (10.1–27.1) | 16.9 (14.6–27.4) |
| BMI (kg/m2) | 25.9 (22.3–30.6) | 26 (25–28.6) |
| Creatinine (mg/dl)* | 0.9 (0.8–1.1) | 1.0 (0.9–1.4) |
| HbA1c | ||
| Percent | 8.8 ± 1.22 | 9.1 ± 1.3 |
| Distribution (%) | 8.3 (7.8–9.7) | 8.8 (8.3–9.7) |
| >10.5% | 5 (31.3) | 5 (33.3) |
| Goal range | ||
| 80–120 mg/dl (4.4–6.7 mmol/l) | 9 (56.3) | 9 (60) |
| 100–140 mg/dl (5.5–7.8 mmol/l) | 7 (43.7)† | 6 (40) |
| Insulin pump | 5 (31.3) | 5 (33.3) |
| Hypoglycemic unawareness | 7 (43.8) | 5 (33.3) |
| Daily insulin units | ||
| Total dose | 47 ± 19 | 50 ± 14 |
| Total basal dose | 25 ± 12 | 26 ± 10 |
| Total bolus dose | 23 ± 10 | 25 ± 6 |
| Characteristics . | Control . | Intervention . |
|---|---|---|
| n | 16 | 15 |
| Age (years) | 44 (32.3–46.8) | 41.8 (24.4–52.7) |
| Sex (% women) | 11 (68.8) | 10 (66.7) |
| Diabetes duration (years) | 17.2 (10.1–27.1) | 16.9 (14.6–27.4) |
| BMI (kg/m2) | 25.9 (22.3–30.6) | 26 (25–28.6) |
| Creatinine (mg/dl)* | 0.9 (0.8–1.1) | 1.0 (0.9–1.4) |
| HbA1c | ||
| Percent | 8.8 ± 1.22 | 9.1 ± 1.3 |
| Distribution (%) | 8.3 (7.8–9.7) | 8.8 (8.3–9.7) |
| >10.5% | 5 (31.3) | 5 (33.3) |
| Goal range | ||
| 80–120 mg/dl (4.4–6.7 mmol/l) | 9 (56.3) | 9 (60) |
| 100–140 mg/dl (5.5–7.8 mmol/l) | 7 (43.7)† | 6 (40) |
| Insulin pump | 5 (31.3) | 5 (33.3) |
| Hypoglycemic unawareness | 7 (43.8) | 5 (33.3) |
| Daily insulin units | ||
| Total dose | 47 ± 19 | 50 ± 14 |
| Total basal dose | 25 ± 12 | 26 ± 10 |
| Total bolus dose | 23 ± 10 | 25 ± 6 |
Data are means ± SD, n (%), or median (IQR).*To convert to Système International (SI) units (μmol/l), multiply values by 88.4; †one patient had a glucose goal range of 90–150 mg/dl (5–8.3 mmol/l).